Literature DB >> 28482505

siRNA-nanoparticle conjugate in gene silencing: A future cure to deadly diseases?

Rituparna Acharya1, Suman Saha2, Sayantan Ray2, Sugata Hazra1, Manoj K Mitra1, Jui Chakraborty3.   

Abstract

Alzheimers, cancer, acquired immune deficiency syndrome (AIDS) are considered to be some of the most deadly diseases of the 21st century on account of their severity and rapid increase in the number of affected population and with scarce cases of recovery, they still remain a troubling paradox. Specifically, with millions of cancer patients worldwide and lack of proper cure for the same, understanding the deadly disease at the molecular level and planning a therapeutic strategy in the same line is the need of the hour. Further, the potential threat of prevalence and escalation of Alzheimer's and HIV (human immunodeficiency virus) infection by more than three times as of recent past, needs a medical breakthrough to arrive at a meaningful solution to tackle the present day scenario. It is evident that these diseases initiate and propagate based on certain genes and their expression which needs to be silenced by the help of small interfering RNA (siRNA) by at least 70%. For short term silencing of the protein coding genes, siRNA is the most appropriate tool. Hence, the present communication explores the possibility for treatment and cure of a plethora of deadly diseases, e.g., cancer, including Alzheimer's and AIDS to some extent, emphatically at the molecular level, using the current trend of RNAi (RNA interference) delivery via a wide variety of nanoparticles.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Biocompatibility; Cancer; Gene silencing; RNAi; siRNA-nanoparticle conjugates

Mesh:

Substances:

Year:  2017        PMID: 28482505     DOI: 10.1016/j.msec.2017.03.009

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  6 in total

1.  Non-covalent Encapsulation of siRNA with Cell-Penetrating Peptides.

Authors:  Martina Tuttolomondo; Henrik J Ditzel
Journal:  Methods Mol Biol       Date:  2021

2.  Inhibition of HBV replication by delivering the dual-gene expression vector pHsa-miR16-siRNA in HepG2.2.15 cells.

Authors:  Wei Wei; Su-Fei Wang; Bing Yu; Ming Ni
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

Review 3.  Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment.

Authors:  Sanjay Kumar; Anchita Diwan; Parinita Singh; Shikha Gulati; Devanshu Choudhary; Ayush Mongia; Shefali Shukla; Akanksha Gupta
Journal:  RSC Adv       Date:  2019-08-01       Impact factor: 4.036

4.  Nischarin-siRNA delivered by polyethylenimine-alginate nanoparticles accelerates motor function recovery after spinal cord injury.

Authors:  Yue-Min Ding; Yu-Ying Li; Chu Wang; Hao Huang; Chen-Chen Zheng; Shao-Han Huang; Yang Xuan; Xiao-Yi Sun; Xiong Zhang
Journal:  Neural Regen Res       Date:  2017-10       Impact factor: 5.135

5.  Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles.

Authors:  Jingtong Pan; Wenyi Ruan; Mengyao Qin; Yueming Long; Tao Wan; Kaiyue Yu; Yuanhao Zhai; Chuanbin Wu; Yuehong Xu
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

6.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.